Management of disease- and treatment-related complications in patients with multiple myeloma.
Treatment of myeloma has dramatically changed after introduction of novel agents, such as thalidomide, lenalidomide and bortezomib, with a significant improvement in response rate and survival of patients with myeloma. For newly diagnosed patients not eligible for transplant, the standards of care are now considered melphalan and prednisone (MP) plus thalidomide and MP plus bortezomib. Ongoing randomized trials are evaluating lenalidomide plus MP and lenalidomide plus dexamethasone. For newly diagnosed patients eligible for transplant, new induction regimens included the combination of high-dose dexamethasone plus thalidomide, high-dose dexamethasone plus lenalidomide (RD) and high-dose dexamethasone plus bortezomib (VD). The combinations RD, VD and bortezomib plus pegylated-liposomal-doxorubicin have received the US Food and Drug Administration approval for the treatment of relapsed myeloma. Different efficacious regimens are therefore now available for patients with myeloma. Disease control leads to improvement of all myeloma-related complications (anemia, bone disease, immune dysfunction and renal impairment), but physicians should take into account the choice of the therapeutic strategy, the expected toxicity profile of each of these regimens, together with the patient's biologic age and comorbidities. Supportive care is an essential part of myeloma therapy, both for the treatment of myeloma-related complications, together with anti-myeloma treatment, and for the management of treatment-emergent adverse events. This chapter will provide an overview of frequency and management of main complications related to the disease itself and to the use of new drugs in newly diagnosed and relapsed patients with myeloma.
Gay
Francesca
F
Divisione di Ematologia dell'Università di Torino, Azienda Ospedaliera S. Giovanni Battista, Ospedale Molinette, Turin, Italy.
Palumbo
Antonio
A
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D009101:Multiple Myeloma / Q000150:complications* / Q000188:drug therapy
J Clin Oncol. 2009 Aug 1;27(22):3664-70
19451428
Br J Haematol. 2009 Mar;144(6):895-903
19170677
Leukemia. 2008 Aug;22(8):1479-84
18509352
J Clin Oncol. 2008 Jan 20;26(3):480-92
18056678
Lancet Oncol. 2010 Jan;11(1):29-37
19853510
Hematol Oncol Clin North Am. 2007 Dec;21(6):1231-46, xi
17996596
Blood. 2008 Apr 15;111(8):3968-77
18245666
Leuk Lymphoma. 2009 May;50(5):764-72
19330654
Int J Radiat Oncol Biol Phys. 1993 Apr 2;25(5):801-4
7683017
Mayo Clin Proc. 2007 Oct;82(10):1179-84
17908524
N Engl J Med. 2007 Nov 22;357(21):2123-32
18032762
N Engl J Med. 2007 Nov 22;357(21):2133-42
18032763
N Engl J Med. 2005 Jun 16;352(24):2487-98
15958804
Am J Med. 2009 Feb;122(2 Suppl):S33-45
19187811
Br J Haematol. 2006 Feb;132(4):410-51
16412016
N Engl J Med. 2008 Aug 28;359(9):906-17
18753647
Ann Oncol. 2009 Aug;20(8):1303-17
19465418
Arch Intern Med. 1998 Sep 28;158(17):1889-93
9759684
N Engl J Med. 2004 Oct 28;351(18):1860-73
15509819
J Clin Oncol. 2009 Apr 10;27(11):1788-93
19273705
Blood. 2008 Sep 1;112(5):1593-9
18574024
Clin Lymphoma Myeloma. 2008 Aug;8(4):237-40
18765311
Haematologica. 2007 Apr;92(4):546-9
17488666
Lancet. 2006 Mar 11;367(9513):825-31
16530576
Blood. 2006 Nov 15;108(10):3289-94
16873668
J Clin Oncol. 2006 Jan 20;24(3):431-6
16365178
Kidney Int. 2001 Oct;60(4):1366-77
11576350
Lancet. 2007 Oct 6;370(9594):1209-18
17920916
Leukemia. 2008 Feb;22(2):414-23
18094721
J Clin Oncol. 2007 Sep 1;25(25):3892-901
17679727
J Clin Oncol. 2007 Oct 1;25(28):4459-65
17785703
Am J Hematol. 1990 Feb;33(2):86-9
2301376
J Clin Oncol. 2008 May 1;26(13):2171-7
18362366